skip to Main Content

Adagrasib Active, Safe Among Patients with KRAS G12C-Mutated Pancreatic, GI Tumors

Newsfeed image, light gray text on dark gray background
Adagrasib induced promising clinical activity as monotherapy among pretreated patients with unresectable or metastatic pancreatic cancer and other gastrointestinal tumors that harbor a KRAS G12C mutation, according to study results.

The agent also had a manageable safety profile, research presented at ASCO Gastrointestinal Cancers Symposium showed. Read more . . . 

Back To Top